- Report
- August 2022
- 115 Pages
Global
From €4090EUR$4,500USD£3,502GBP
- Report
- January 2024
- 250 Pages
Global
From €7226EUR$7,950USD£6,187GBP
- Report
- October 2018
- 19 Pages
Global
From €9089EUR$10,000USD£7,783GBP
- Report
- October 2018
- 16 Pages
Global
From €9089EUR$10,000USD£7,783GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €454EUR$500USD£389GBP
Tracleer is a cardiovascular drug used to treat pulmonary arterial hypertension (PAH). It is a type of endothelin receptor antagonist (ERA) that works by blocking the action of endothelin, a substance in the body that can cause the blood vessels in the lungs to narrow. This narrowing can lead to high blood pressure in the lungs, which can cause shortness of breath, fatigue, and other symptoms. Tracleer is used to reduce the symptoms of PAH and improve the patient's quality of life.
Tracleer is marketed by Actelion Pharmaceuticals, a Swiss biopharmaceutical company. Other companies in the market include Gilead Sciences, GlaxoSmithKline, and Bayer. Show Less Read more
